CTI BioPharma Corp
CTI BioPharma Has Fallen Almost 39% Today
On July 18, CTI BioPharma announced the outcome of its type B meeting with the FDA related to its investigational drug pacritinib.
How Is Novartis’s Kymriah Positioned for 2018?
FDA and EC approvals for label expansion are expected to further boost Kymriah’s sales growth.